Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis

Completed

• Conditions: Arthritis, Psoriatic; Psoriasis
• Interventions: Other: questionnaire

• Registration Number: NCT00998829
• Lead Sponsor: Pfizer

Brief Summary

This study aims to collect Australian data on the prevalence of undiagnosed psoriatic arthritis in patients with plaque psoriasis. In addition the study will assess disease severity and quality of life in Australian patients with psoriasis attending specialist dermatology clinics.

Detailed Description

Consecutive psoriasis patients seen at each site will be invited to participate in the study

Study Timeline

• Study First Submitted: 2009-10-20
• Study First Submitted QC: 2009-10-20
• Study First Posted: 2009-10-21
• Study Start: 2010-05
• Primary Completion: 2012-05
• Study Completion: 2012-05
• Status Verified: 2012-11
• Last Update Submitted: 2012-11-28
• Last Update Posted: 2012-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 458

Inclusion Criteria

• Diagnosis of plaque psoriasis
• >= 18 years of age
• Able to complete English-language questionnaires

Exclusion Criteria

• Participation in an interventional clinical trial in previous 3 months
• Known rheumatologist-confirmed psoriatic arthritis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Study population	questionnaire	The group comprises the entire study population

Primary Outcome Measures

Name	Time	Method
To evaluate the prevalence of undiagnosed psoriatic arthritis in patients presenting with plaque psoriasis using the PASE (Psoriatic Arthritis Screening and Evaluation) questionnaire based on a score of ≥ 44 on the questionnaire	14 days
Evaluate the positive predictive value between PASE (Psoriatic Arthritis Screening and Evaluation) score ≥ 44 and rheumatologist-confirmed diagnosis of psoriatic arthritis in a population of tertiary Australian psoriasis patients	14 days

Secondary Outcome Measures

Name	Time	Method
Evaluate the proportion of patients within the enrolled patient population with moderate-to-severe plaque psoriasis (PASI [Psoriasis Area and Severity Index] > 10)	1 day
Evaluate the proportion of patients in a tertiary population with moderate-to-severe psoriasis with respect to treatment history and current treatment	1 day
Describe quality of life (QoL) in a tertiary psoriasis patient population	1 day
Explore the relationship between disease severity and QoL (quality of life) and stratified by the presence or absence of psoriatic arthritis in a tertiary population	14 days

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇦🇺 Parkville, Victoria, Australia